Research News and Research

RSS

New finding may lead to development of immunity-based therapies for tuberculosis

A study by researchers at UT Southwestern Medical Center has identified how an enzyme involved in protecting the body from pathogens senses Mycobacterium tuberculosis (TB), a bacterial pathogen that infects millions of people worldwide and causes about 1.5 million deaths annually.

2 Jun 2015

Leica Microsystems to acquire OCT company Bioptigen

Bioptigen develops and manufactures innovative OCT systems and software and is globally successful with products for clinical as well as translational research applications. Using low-power, near-infrared light, Bioptigen OCTs generate high-resolution, volumetric images of the eye...

From Leica Microsystems GmbH 2 Jun 2015

ASCO 2015: Berg presents data from BPM 31510 Phase Ib trial for solid tumors

Berg, a biopharmaceutical company committed to uncovering health solutions through a data-driven, biological approach, presented clinical research from its trials using its cancer drug BPM 31510 on Phase Ib solid tumors and preclinical data on triple negative breast cancer, at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), May 29 – June 2 in Chicago.

2 Jun 2015

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

OncoGenex Pharmaceuticals, Inc. announced that results from an exploratory analysis of the Phase 2 Borealis-1 trial showed that metastatic bladder cancer patients with poor prognostic features benefited from apatorsen 600mg added to first-line chemotherapy compared to chemotherapy alone.

2 Jun 2015

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis®

2 Jun 2015

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis®

2 Jun 2015

Elusys’ Anthim BLA to treat inhalational anthrax accepted for review by the FDA

Elusys Therapeutics, Inc. today announced the U.S. Food and Drug Administration has accepted for filing and review its Biologics License Application for Anthim® (obiltoxaximab) for the treatment and prevention of inhalational anthrax, a top bioterror threat which was submitted on March 20, 2015. Anthim is a candidate for future acquisition into the Strategic National Stockpile, the U.S. government's repository of critical medical supplies for biowarfare preparedness.

2 Jun 2015

EMA grants Orphan Drug Designation to Stempeucel for treatment of Thromboangiitis Obliterans

Stempeutics Research, a group company of Manipal Education & Medical Group and a joint venture with Cipla Group, announced today that the European Medicines Agency (EMA) has granted Orphan Drug Designation for its drug Stempeucel® for the treatment of Thromboangiitis Obliterans.

2 Jun 2015

Vitamin D and calcium supplements may not help relieve menopausal symptoms, reveals study

Women who took vitamin D and calcium supplements had the same number of menopausal symptoms as women who did not take the supplements, according to a study published today in Maturitas, the official journal of the European Menopause and Andropause Society.

2 Jun 2015

Zecotek’s switchable 3D/2D optical imaging system granted U.S. Patent

Zecotek Photonics Inc., a developer of leading-edge photonics technologies for industrial, healthcare and scientific markets, is pleased to announce that the U.S. Patent office has granted U.S. Patent No. 9,055,288 to Zecotek for technology related to the Company's switchable 3D/2D optical imaging system.

2 Jun 2015

MedImmune, AstraZeneca present encouraging results from new combination-focused immuno-oncology portfolio at ASCO 2015

AstraZeneca and MedImmune, the company’s global biologics research and development arm, today presented encouraging results from their novel combination-focused immuno-oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting 2015.

2 Jun 2015

Experimental drug and common antibiotic combination holds promise for pancreatic cancer treatment

Despite surgical advances, pancreatic cancer continues to be one of the most deadly and difficult cancers to manage due to a lack of effective therapies. However, VCU Massey Cancer Center and VCU Institute of Molecular Medicine (VIMM) scientists in the lab of Paul B. Fisher, M.Ph., Ph.D., are hoping to change that with a novel combination of an experimental drug and a common antibiotic that has shown promising results in preclinical experiments.

2 Jun 2015

DNA Therapeutics to present DT01 phase 1/2a trial results at ASCO 2015

DNA Therapeutics, a private biopharmaceutical company developing DT01, a first-in-class clinical pan DNA repair inhibitor to treat tumors resistant to conventional treatments, will today present the results of the first-in-man phase 1/2a trial of DT01 in combination with radiation therapy in patients with cutaneous metastatic melanoma.

2 Jun 2015

Intermountain Precision Genomics: Precision medicine can benefit advanced cancer patients without increasing costs

Two new studies conducted by Intermountain Healthcare’s Intermountain Precision Genomics reveal that precision medicine can improve survival in advanced cancer patients – and do so without increasing costs.

2 Jun 2015

$Matched therapy and FoundationOne genomic profiling improve outcomes in patients with refractory cancer$

Matched therapy and FoundationOne genomic profiling improve outcomes in patients with refractory cancer

Foundation Medicine, Inc. and collaborators from the University of Texas MD Anderson Cancer Center and Sarah Cannon Research Institute at HealthOne today announced compelling new data demonstrating that matching patients to targeted therapies based on the unique molecular profile of the patient’s advanced cancer leads to improved outcomes across a variety of key measures, including overall survival.

2 Jun 2015

Boehringer Ingelheim presents afatinib LUX-Lung 8 trial data at ASCO 2015

Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy.

2 Jun 2015

New treatment option for postmenopausal women with non-invasive breast cancer

Anastrozole provides a significant benefit compared with tamoxifen in preventing recurrence after a lumpectomy and radiation therapy in postmenopausal women ages 60 years or younger who had DCIS (ductal carcinoma in situ), a common diagnosis of non-invasive breast cancer. In women over age 60, it works as well as tamoxifen.

2 Jun 2015

Two new groups of viruses discovered within Bunyavirus family in Ivory Coast tropical forest

Researchers at the University of Bonn and the German Center for Infection Research (DZIF) have discovered two new groups of viruses within the Bunyavirus family in the tropical forest of Ivory Coast. Previously only five groups responsible for serious illnesses in humans and animals were known.

2 Jun 2015

Civilian doctors not adequately trained to treat veterans, new survey finds

A survey of nearly 150 U.S. physicians who frequently treat veterans found civilian doctors aren't adequately trained in health issues related to military service, according to research published today in The Journal of the American Osteopathic Association.

2 Jun 2015

Four month old babies can perceive faces

Scientists from the University of Louvain have discovered that a key element of infant brain development occurs years earlier than previously thought.

2 Jun 2015

Research News and Research

New finding may lead to development of immunity-based therapies for tuberculosis

Leica Microsystems to acquire OCT company Bioptigen

ASCO 2015: Berg presents data from BPM 31510 Phase Ib trial for solid tumors

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

Elusys’ Anthim BLA to treat inhalational anthrax accepted for review by the FDA

EMA grants Orphan Drug Designation to Stempeucel for treatment of Thromboangiitis Obliterans

Vitamin D and calcium supplements may not help relieve menopausal symptoms, reveals study

Zecotek’s switchable 3D/2D optical imaging system granted U.S. Patent

MedImmune, AstraZeneca present encouraging results from new combination-focused immuno-oncology portfolio at ASCO 2015

Experimental drug and common antibiotic combination holds promise for pancreatic cancer treatment

DNA Therapeutics to present DT01 phase 1/2a trial results at ASCO 2015

Intermountain Precision Genomics: Precision medicine can benefit advanced cancer patients without increasing costs

Matched therapy and FoundationOne genomic profiling improve outcomes in patients with refractory cancer

Boehringer Ingelheim presents afatinib LUX-Lung 8 trial data at ASCO 2015

New treatment option for postmenopausal women with non-invasive breast cancer

Two new groups of viruses discovered within Bunyavirus family in Ivory Coast tropical forest

Civilian doctors not adequately trained to treat veterans, new survey finds

Four month old babies can perceive faces

Industry Focus eBook - Life Science Microscopy (3rd Edition) eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (3rd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation